366 related articles for article (PubMed ID: 9566412)
21. Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics.
Scheffler MR; Colburn W; Kook KA; Thomas SD
Clin Pharmacol Ther; 1999 May; 65(5):483-90. PubMed ID: 10340913
[TBL] [Abstract][Full Text] [Related]
22. Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications.
Goldzieher JW
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):318-22. PubMed ID: 2196804
[TBL] [Abstract][Full Text] [Related]
23. Prospective study of carbohydrate metabolism in women using a triphasic oral contraceptive containing norethindrone and ethinyl estradiol for 3 months.
Spellacy WN; Ellingson AB; Kotlik A; Tsibris JC
Am J Obstet Gynecol; 1988 Oct; 159(4):877-9. PubMed ID: 3052079
[TBL] [Abstract][Full Text] [Related]
24. Control of fertility with oral medication.
Diddle AW; Watts GF; Gardner WH; Williamson PJ
West J Surg Obstet Gynecol; 1964; 72():222-9. PubMed ID: 12305556
[TBL] [Abstract][Full Text] [Related]
25. Single and multiple administration of a new triphasic oral contraceptive to women: pharmacokinetics of ethinyl estradiol and free and total testosterone levels in serum.
Kuhnz W; Sostarek D; Gansau C; Louton T; Mahler M
Am J Obstet Gynecol; 1991 Sep; 165(3):596-602. PubMed ID: 1892184
[TBL] [Abstract][Full Text] [Related]
26. Serum lipids and lipoproteins during treatment with oral contraceptives containing natural and synthetic oestrogens. A controlled double-blind investigation.
Bostofte E; Hemmingsen L; Møller KJ; Serup J; Weber T
Acta Endocrinol (Copenh); 1978 Apr; 87(4):855-64. PubMed ID: 347855
[TBL] [Abstract][Full Text] [Related]
27. Oral contraceptives stimulate the excretion of clofibric acid glucuronide in women and female rats.
Liu HF; Magdalou J; Nicolas A; Lafaurie C; Siest G
Gen Pharmacol; 1991; 22(2):393-7. PubMed ID: 1905251
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles.
Kuhnz W; Staks T; Jütting G
Contraception; 1993 Dec; 48(6):557-75. PubMed ID: 8131397
[TBL] [Abstract][Full Text] [Related]
29. Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women.
Baumann A; Fuhrmeister A; Brudny-Klöppel M; Draeger C; Bunte T; Kuhnz W
Contraception; 1996 Oct; 54(4):235-42. PubMed ID: 8922877
[TBL] [Abstract][Full Text] [Related]
30. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects.
Doose DR; Wang SS; Padmanabhan M; Schwabe S; Jacobs D; Bialer M
Epilepsia; 2003 Apr; 44(4):540-9. PubMed ID: 12681003
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol.
Archer DF; Timmer CJ; Lammers P
Fertil Steril; 1994 Apr; 61(4):645-51. PubMed ID: 8150105
[TBL] [Abstract][Full Text] [Related]
32. Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive.
Yu Z; Yu D; Walker PS; Tang-Liu DD
Clin Pharmacokinet; 2004; 43(10):673-84. PubMed ID: 15244497
[TBL] [Abstract][Full Text] [Related]
33. Norgestimate: a clinical overview of a new progestin.
Bringer J
Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1969-77. PubMed ID: 1605287
[TBL] [Abstract][Full Text] [Related]
34. Bioequivalence of two oral contraceptive drugs containing norethindrone and ethinyl estradiol.
Saperstein S; Edgren RA; Lee GJ; Jung D; Fratis A; Kushinsky S; Mroszczak E; Dorr A
Contraception; 1989 Nov; 40(5):581-90. PubMed ID: 2612166
[TBL] [Abstract][Full Text] [Related]
35. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding.
Murphy PA; Kern SE; Stanczyk FZ; Westhoff CL
Contraception; 2005 Jun; 71(6):402-8. PubMed ID: 15914127
[TBL] [Abstract][Full Text] [Related]
36. Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers.
Inglis AM; Miller AK; Culkin KT; Finnerty D; Patterson SD; Jorkasky DK; Freed MI
J Clin Pharmacol; 2001 Jun; 41(6):683-90. PubMed ID: 11402638
[TBL] [Abstract][Full Text] [Related]
37. Drug interactions with oral contraceptive preparations.
Shenfield GM
Med J Aust; 1986 Feb; 144(4):205-11. PubMed ID: 2868406
[TBL] [Abstract][Full Text] [Related]
38. Progestogens and arterial disease--evidence from the Royal College of General Practitioners' study.
Kay CR
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):762-5. PubMed ID: 6801981
[TBL] [Abstract][Full Text] [Related]
39. Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone.
Schöller-Gyüre M; Kakuda TN; Woodfall B; Aharchi F; Peeters M; Vandermeulen K; Hoetelmans RM
Contraception; 2009 Jul; 80(1):44-52. PubMed ID: 19501215
[TBL] [Abstract][Full Text] [Related]
40. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
